Chronic Disease

Why ALS damages some nerve cells that control muscle movement but spares others remains unclear. Stanford Medicine’s Aaron Gitler and colleagues are searching for answers.

Knight Initiative researchers have identified molecular changes in vulnerable neurons that could point to new ALS treatments.

Research shows that obexelimab halves relapse risk in patients with IgG4-related disease, a chronic immune condition often misdiagnosed as cancer.

Two existing drugs improve mucus clearance in animal models of cystic fibrosis, indicating a potential pathway to reduce chronic lung infections in humans.

An antibody-based approach for Fanconi anemia replaces traditional toxic conditioning with targeted therapy, allowing safe restoration of blood and immune function without chemotherapy or radiation.

New research suggests that certain genetic variants can decrease the ability of GLP-1 diabetes drugs to regulate blood sugar – a mysterious phenomenon known as GLP-1 resistance.

A calorie-restrictive diet significantly alleviates symptoms of mild-to-moderate Crohn’s disease, offering new guidance for patients.

A key molecule involved in red blood cell production governs whether the immune system attacks or tolerates cells.

The discovery could also open a new path for treating autoimmune diseases and improving organ transplants.

A study led by Stanford Medicine reveals that an unusual type of fat that forms near the intestines in Crohn’s disease can trigger debilitating scars.